Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

NCT03575052 is registered in ClinicalTrials.gov with ACADIA Pharmaceuticals Inc. as lead sponsor.

NCT NCT03575052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03575052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Lead sponsor
ACADIA Pharmaceuticals Inc.
Phase
Phase 3
Overall status
Completed
Start date
May 21, 2018
Completion date
May 6, 2022
Enrollment
784 (actual)
Sites
104

Conditions

As the registry lists them; a condition with its own page is linked.

neuropsychiatric symptoms related to neurodegenerative disease